Menu
Solutions
Solutions for Integrated Delivery Networks
Solutions for Community Cancer Centers
Solutions for Academic Institutions and NCI-Designated Cancer Centers
Solutions for Life Science
Solution OLD
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
About Us
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
Solutions
Next Level Multidisciplinary Cancer Care Solutions for Cancer Centers, Oncology Practices and Life Science Organizations
Academic and NCI
Cancer Center Solutions
Leading institutions rely on OncoLens to drive clinical trial research, multidisciplinary care, and affiliate network engagement.
Community Cancer
Center Solutions
100+ community cancer centers and oncology practices use OncoLens to improve patient access to next level multidisciplinary care, accreditations, and quality improvement.
Integrated Delivery Network (IDN) Solutions
The OncoLens platform drives standardization and provider engagement across the entire network.
Life Sciences Solutions
Life Sciences Organizations work with OncoLens to collaborate with its oncology network, the largest in the United States.
Next Level
Multidisciplinary Cancer Care
Explore the OncoLens Platform
Solution OLD
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
Project ECHO® Learning Series
Expert-led telementoring sessions focused on irAE monitoring and management strategies for approved cancer immunotherapies.
LEARN MORE and REGISTER
Hosted by ACCC and Boston University. Sponsored by Bristol Myers Squibb.
Powered by OncoLens.
OncoLens Resources
All Resources
Blog
Case Studies
Education
CME
News and Events
About
OncoLens provides a first of its kind
multidisciplinary care platform.
More than 10% of all cancer centers in the United States count on OncoLens to help improve outcomes through coordinated patient data, in-depth analysis, and actionable clinical decision support.
2,000,000+
Patients under Care in 200+ Cancer Centers
118,000+
Multidisciplinary Case Discussions
19,000+
Comprehensive Tumor Conferences
About OncoLens
About Us
Meet Our Leadership Team
Awards
Meet Our Board of Directors
Contact Us
Careers
Careers
SCHEDULE A DEMO
Education
Quality Improvement Program Webinar—Breast and Ovarian Cancer Biomarker Testing
Topics —
Breast Cancer
,
Ovarian Cancer
Mar 15, 2022
|
Education
Quality Improvement Program Webinar—NSCLC Biomarker Testing
Topics —
NSCLC
Mar 8, 2022
|
Education
Lung Cancer Patient with 3 EGFR Mutations
Topics —
EGFR
,
Lung Cancer
Apr 1, 2021
|
Education
Ovarian Cancer Patient with Somatic BRCA1 Reversion Mutation
Topics —
BRCA
,
Ovarian Cancer
Apr 1, 2021
|
Education
Ovarian and Lung Cancer Patients with BRCA Reversion and Three EGFR Mutations
Topics —
BRCA
,
EGFR
,
Lung Cancer
,
Ovarian Cancer
Apr 1, 2021
|
Education
NCCN updates: Stage IB – IIA NSCLC with EGFR Alteration Patients
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
,
NSCLC
Mar 1, 2021
|
Education
Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
Mar 1, 2021
|
Education
NSCLC Patient and Adjuvant Chemotherapy
Topics —
EGFR
,
Lung Cancer
,
NSCLC
Mar 1, 2021
|
Education
Patient with Possible Synchronous Early-stage NSCLC and Different DetermaRx Results
Topics —
Lung Cancer
,
NSCLC
Feb 1, 2021
|
Education
Patient with NSCLC Who Recurred within a Year
Topics —
EGFR
,
Lung Cancer
,
NSCLC
Feb 1, 2021
|
Education
Patient with Stage IB NSCLC, an Oncocyte DetermaRx High-Risk Result and an EGFR Exon 19 Deletion
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
,
NSCLC
Feb 1, 2021
|
Education
Stratification of Early-Stage, Non-squamous NSCLC Patients Likely to Benefit from Early, Post-operative Chemotherapy
Topics —
EGFR
,
Exon 19 Deletion
,
Lung Cancer
,
NSCLC
Feb 1, 2021
|
Education
MTC: Patient with Stomach Cancer and KIT exon 11 and ATM Mutations
Topics —
ATM
,
Gastric Cancer
,
KIT Exon 11
Dec 1, 2020
|
Education
Patient with Prostate Cancer and CDK12 and TP53 Mutations
Topics —
CDK12
,
Prostate Cancer
,
TP53
Dec 1, 2020
|
Education
MTB Discussion for Patients with KIT and CDK12 Mutations
Topics —
ATM
,
CDK12
,
Gastric Cancer
,
KIT Exon 11
,
Prostate Cancer
,
TP53
Dec 1, 2020
|
Education
Overview of New CoC Standards
Topics —
CoC
Jan 1, 2020
|
Education
Blog
Case Studies
CME
Education
News and Events